Phase I/II Study of Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Locally Advanced or Metastatic Unresectable Non Small Cell Lung Cancer

NCT00082472 Phase 1/Phase 2 UNKNOWN

This study is intended to show whether inhaled chemotherapy can be added to a standard IV chemotherapy regime, to investigate the additional toxicities and to show initial evidence of efficacy of the combination.

Details

Lead sponsor	Zivena
Phase	Phase 1/Phase 2
Status	UNKNOWN
Enrolment	30
Start date	2004-01

Conditions

• NSCLC

Interventions

• Doxorubicin HCl Inhalation Solution
• Docetaxel
• Cisplatin

Countries

United States